Literature DB >> 33299833

Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.

Toshiharu Sakurai1, Naoshi Nishida1, Masatoshi Kudo1.   

Abstract

Year:  2020        PMID： 33299833      PMCID： PMC7720063          DOI： 10.21037/hbsn.2020.03.04

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

1.  Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-01-15       Impact factor: 11.740

2.  Combination Cancer Immunotherapy in Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-01-31       Impact factor: 11.740

3.  Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-07-09       Impact factor: 11.740

4.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

5.  Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins.

Authors:  Jack D Bui; Ravindra Uppaluri; Chyi-Song Hsieh; Robert D Schreiber
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

6.  IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.

Authors:  Florian R Greten; Lars Eckmann; Tim F Greten; Jin Mo Park; Zhi-Wei Li; Laurence J Egan; Martin F Kagnoff; Michael Karin
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

7.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.

Authors:  Toshiharu Sakurai; Guobin He; Atsushi Matsuzawa; Guann-Yi Yu; Shin Maeda; Gary Hardiman; Michael Karin
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

8.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

9.  Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.

Authors:  Shu-Xiang Cui; Wen-Na Shi; Zhi-Yu Song; Shu-Qing Wang; Xin-Feng Yu; Zu-Hua Gao; Xian-Jun Qu
Journal:  Oncotarget       Date:  2016-06-14

10.  SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.

Authors:  Hyo Jeong Kang; Dal-Hee Chung; Chang Ohk Sung; Su Hyun Yoo; Eunsil Yu; Nayoung Kim; Sy-Hye Lee; Ji-Young Song; Chong Jai Kim; Jene Choi
Journal:  Oncotarget       Date:  2017-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.